title: Development of sarcoidosis during adalimumab therapy for chronic plaque psoriasis.
abstract: A 38-year-old woman developed clinical, biochemical, radiological and histopathological evidence of cutaneous and pulmonary sarcoidosis 5 months after commencing adalimumab for chronic plaque psoriasis. Signs and symptoms resolved within 3 months of cessation of adalimumab.
authors.affiliation: Skin and Cancer Foundation, Melbourne, Victoria, Australia. smarcella@skincancer.asn.au
authors.forename: Stefanie
authors.initials: S
authors.lastname: Marcella
authors.forename: Belinda
authors.initials: B
authors.lastname: Welsh
authors.forename: Peter
authors.initials: P
authors.lastname: Foley
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D011565:Psoriasis / Q000188:drug therapy*; D012507:Sarcoidosis / Q000139:chemically induced* / Q000175:diagnosis; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000893:Anti-Inflammatory Agents; D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab